Endometrial Cancer Market Size Set for Steady Growth Through 2034

The Endometrial Cancer market is expected to expand at a notable compound annual growth rate (CAGR) throughout the forecast period from 2020 to 2034. DelveInsight’s comprehensive market research provides critical insights into such market trends, enabling stakeholders to understand growth drivers, emerging opportunities, and potential challenges within the Endometrial Cancer landscape.

As per the corporate presentation of Karyopharm Therapeutics 2025, the company is anticipating the Phase III trial (XPORT-EC-042) data, evaluating selinexor as a maintenance treatment for patients with TP53 wild-type advanced or recurrent endometrial cancer, by mid-2026.

In the US, approximately, 67,880 women were diagnosed with endometrial cancer in 2024. In 2022, the endometrial cancer cases were 66,055 in the US, 11,767 in Germany, 9,760 in France, 10,202 in Spain, 10,440 in the UK, and 18,338 in Japan. In 2020, there were 130,051 estimated incident cases of endometrial cancer in Europe, and there were 29,963 deaths. In Spain, endometrial cancer is the fourth most common cancer in women (behind breast, lung, and colon and rectal cancer). It has an incidence per 100,000 women of 13-14 cases per year, with a mortality of 3-4 cases.

In Spain, the average age of diagnosis is 63 years. Although most patients are diagnosed after 55 years of age, up to 25% of cases are identified before that age, and 5-6% between 35 and 44 years of age. In females in the UK, uterine cancer is the fourth most common cancer, with around 9,800 new cases every year. In Europe, approximately 69–75% of patients with endometrial cancer have pMMR/MSS tumours. The incidence of endometrial cancer throughout Asia is heterogeneous, with 10.2 per 100,000 in Japan.

DelveInsight’s report, “Endometrial Cancer Market Insights, Epidemiology, and Market Forecast-2034” provides a comprehensive analysis of the Endometrial Cancer landscape. The report delivers detailed insights into the disease, including historical and projected epidemiology, helping stakeholders understand the prevalence, incidence, and patient demographics across key regions.

Additionally, it examines Endometrial Cancer market dynamics, offering a thorough assessment of current and emerging market trends, treatment patterns, and therapeutic developments. The analysis spans major markets, including the United States, EU4 (Germany, Spain, Italy, France, and the United Kingdom), and Japan, equipping decision-makers with actionable intelligence for strategic planning, investment, and research initiatives.

To Know in detail about the Endometrial Cancer market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Endometrial Cancer Market Forecast

Some of the key facts of the Endometrial Cancer Market Report:

• KEYTRUDA (pembrolizumab) has been in the market since 2021 and has accounted for the majority of the market share for endometrial cancer.
• IMFINZI (durvalumab) and JEMPERLI (dostarlimab) are the other recently FDA-approved therapies (2024) to treat patients with endometrial cancer.
• Key Endometrial Cancer Companies: Merck, AstraZeneca, GSK, Eisai, Karyopharm Therapeutics, and Daiichi Sankyo, Hoffmann-La Roche, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others Companies: Merck, AstraZeneca, GSK, Eisai, Karyopharm Therapeutics, and Daiichi Sankyo, Hoffmann-La Roche, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others
• Key Endometrial Cancer Therapies: KEYTRUDA (Pembrolizumab), JEMPERLI (dostarlimab), LENVIMA (lenvatinib) + KEYTRUDA (pembrolizumab), Sacituzumab tirumotecan (MK-2870), XPOVIO (selinexor), ENHERTU (trastuzumab deruxtecan) ± radiotherapy, Giredestrant (RG6171, GDC-9545), Lifileucel, Imlunestrant, Lynparza (Olaparib) + Imfinzi DuO-E, Selinexor, EG-007, and others

Endometrial Cancer Overview

Endometrial cancer is a type of cancer that arises from the lining of the uterus, known as the endometrium. The endometrium is the tissue that typically undergoes changes during the menstrual cycle in preparation for pregnancy.

Get a Free sample for the Endometrial Cancer Market Report:

https://www.delveinsight.com/report-store/endometrial-cancer-market

Key Trends in Endometrial Cancer Therapeutics Market:

• Rapid adoption of immunotherapy and targeted therapies: Immuno-oncology agents (e.g., PD-1/PD-L1 inhibitors) and targeted drugs are becoming standard of care, especially for advanced and recurrent cases.
• Shift toward precision medicine and biomarker-driven treatment: Increasing use of genomic profiling and molecular diagnostics is enabling personalized treatment strategies, improving efficacy and reducing adverse effects.
• Growing use of combination therapy approaches: Combination regimens (immunotherapy + chemotherapy or targeted agents) are gaining traction to enhance survival outcomes and delay disease progression.
• Strong pipeline and increasing clinical trial activity: A robust pipeline with novel agents and mechanisms of action is driving innovation, supported by increasing R&D investments and regulatory approvals.
• Rising focus on early diagnosis and advanced diagnostics: Advancements such as liquid biopsies and AI-driven diagnostics are improving early detection rates, thereby boosting treatment demand and market growth.

Endometrial Cancer Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Endometrial Cancer Epidemiology Segmentation:

The Endometrial Cancer market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM segmented into:

• Total Incident Cases of Endometrial Cancer
• Subtype-specific Incident Cases of Endometrial Cancer
• Mutation-Specific Incident Cases of Endometrial Cancer
• Age-specific Incident Cases of Endometrial Cancer
• Stage-specific Incident Cases of Endometrial Cancer
• Line-wise Treated Cases of Endometrial Cancer

Download the report to understand which factors are driving Endometrial Cancer epidemiology trends @ Endometrial Cancer Epidemiological Insights

Recent Development In The Endometrial Cancer Treatment Landscape:

• In August 2025, Genmab received FDA Breakthrough Therapy Designation for Rina-S®, its investigational FRα-directed ADC, for treating recurrent or progressive endometrial cancer.
• In June 2025, Daiichi Sankyo has reported that the first patient has been dosed in the DESTINY-Endometrial01 clinical trial, which is assessing Enhertu (trastuzumab deruxtecan) in combination with either rilvegostomig or Merck’s Keytruda (pembrolizumab) as a first-line treatment for patients with HER2-expressing (IHC 3+/2+), mismatch repair proficient (pMMR) advanced or recurrent endometrial cancer.
• In May 2025, AstraZeneca presented the data of the Phase III trial of IMFINZI + carboplatin/paclitaxel, followed by IMFINZI ± LYNPARZA (olaparib) as first-line treatment for endometrial cancer.
• In May 2025, Kaida BioPharma revealed it has signed a manufacturing partnership with Northway Biotech, Inc., a full-service biologics Contract Development and Manufacturing Organization (CDMO), to produce its lead candidate, KAD101. This innovative biologic, a prolactin receptor antagonist, is currently being developed for platinum-resistant ovarian cancer (PROC), with potential to expand into the treatment of endometrial, uterine, and breast cancers.
• In May 2025, PRISM BioLab, Co. Ltd. announced that the analysis of a combination study of E7386 created through collaboration research with Eisai Co., Ltd., and Lenvatinib mesylate will be presented by Eisai at the American Society of Clinical Oncology (ASCO) Congress 2025, held in Chicago, USA from May 30 to June 3, 2025. To determine the optimal dose of E7386 in combination with Lenvatinib in the open-label Phase Ib study (NCT04008797), expansion cohort of advanced endometrial cancer patients who progressed following platinum-based chemotherapy and anti-PD (L)1 immunotherapy have been implemented by Eisai, and the enrollment of 30 patients was completed.
• In May 2025, Combination therapies targeting the PI3K/AKT/mTOR and MAPK/ERK signaling pathways are currently being explored in the treatment of endometrial cancer. The mTOR inhibitors everolimus (Afinitor) and temsirolimus (Torisel) have been investigated in various combination regimens for patients with recurrent disease, aiming to disrupt these critical pathways involved in endometrial tumor development. Despite the evaluation of multiple doublet and triplet combinations, including those involving these agents, clinical outcomes have shown only modest effectiveness.
• In March 2025, Faeth Therapeutics and The GOG Foundation, Inc. (GOG-F) have announced the dosing of the first patient in their Phase II combination trial involving PIKTOR comprising FTH-001 (serabelisib) and FTH-003 (sapanisertib)—alongside paclitaxel. This study represents the most advanced effort to explore a novel dual PI3Kα-mTORC1/2 inhibition strategy aimed at targeting cancer metabolism in individuals with endometrial cancer.

Endometrial Cancer Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Endometrial Cancer market or expected to get launched during the study period. The analysis covers Endometrial Cancer market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Endometrial Cancer Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

To know more about Endometrial Cancer treatment, visit @ Endometrial Cancer Medications

Endometrial Cancer Therapies and Key Companies

• KEYTRUDA (Pembrolizumab): Merck
• IMFINZI (durvalumab): AstraZeneca
• JEMPERLI (dostarlimab): GSK
• LENVIMA (lenvatinib) + KEYTRUDA (pembrolizumab): Eisai and Merck
• Sacituzumab tirumotecan (MK-2870): Merck
• XPOVIO (selinexor): Karyopharm Therapeutics
• ENHERTU (trastuzumab deruxtecan) ± radiotherapy: AstraZeneca and Daiichi Sankyo
• Giredestrant (RG6171, GDC-9545): Hoffmann-La Roche
• Lifileucel: Iovance Biotherapeutics
• Imlunestrant: Eli Lilly
• Lynparza (Olaparib) + Imfinzi DuO-E: AstraZeneca
• Selinexor: Karyopharm Therapeutics
• EG-007: Evergreen Therapeutics

Endometrial Cancer Market Drivers

• Rising Incidence Rates: Increasing prevalence linked to obesity, aging population, and hormonal imbalances is expanding the patient pool.
• Advancements in Targeted and Immunotherapies: Introduction of checkpoint inhibitors, hormonal therapies, and combination regimens is improving treatment outcomes.
• Growing Awareness and Early Diagnosis: Enhanced screening and awareness programs are leading to earlier detection and better prognosis.
• Strong Pipeline and R&D Activity: Ongoing clinical trials and novel drug development are driving innovation in the treatment landscape.
• Favorable Regulatory Support: Accelerated approvals and breakthrough therapy designations are facilitating faster market entry of new treatments.

Endometrial Cancer Market Barriers

• High Treatment Costs: Advanced therapies, especially immunotherapies, can be expensive and limit patient access.
• Side Effects and Safety Concerns: Adverse effects associated with chemotherapy and immunotherapy may impact treatment adherence.
• Limited Efficacy in Advanced Stages: Treatment outcomes remain suboptimal for metastatic or recurrent cases.
• Disparities in Healthcare Access: Limited access to advanced diagnostics and treatments in developing regions restricts market growth.
• Complex Disease Biology: Variability in tumor subtypes and genetic profiles complicates treatment selection and development.

Scope of the Endometrial Cancer Market Report

• Study Period: 2020–2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key Endometrial Cancer Companies: Merck, AstraZeneca, GSK, Eisai, Karyopharm Therapeutics, and Daiichi Sankyo, Hoffmann-La Roche, Karyopharm Therapeutics, Evergreen Therapeutics, Abbott Laboratories, Inc., ARIAD Pharmaceuticals, Inc., Becton, Dickinson and Company, F. Hoffmann, La Roche AG, GlaxoSmithKline PLC, Merck & Co., Inc., Novartis AG. Siemens Healthineers, and others
• Key Endometrial Cancer Therapies: KEYTRUDA (Pembrolizumab), JEMPERLI (dostarlimab), LENVIMA (lenvatinib) + KEYTRUDA (pembrolizumab), Sacituzumab tirumotecan (MK-2870), XPOVIO (selinexor), ENHERTU (trastuzumab deruxtecan) ± radiotherapy, Giredestrant (RG6171, GDC-9545), Lifileucel, Imlunestrant, Lynparza (Olaparib) + Imfinzi DuO-E, Selinexor, EG-007, and others
• Endometrial Cancer Therapeutic Assessment: Endometrial Cancer current marketed and Endometrial Cancer emerging therapies
• Endometrial Cancer Market Dynamics:  Endometrial Cancer market drivers and Endometrial Cancer market barriers
• Endometrial Cancer Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
• Endometrial Cancer Unmet Needs, KOL’s views, Analyst’s views, Endometrial Cancer Market Access and Reimbursement 

Discover more about therapies set to grab major Endometrial Cancer market share @ Endometrial Cancer Treatment Landscape

About DelveInsight 

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.